Ireland has solidified its position as a premier global hub for the biopharmaceutical industry. With over 85 pharmaceutical companies operating in the country, including 9 of the top 10 global giants, the Irish sector contributes significantly to the global supply of vaccines and biologicals. As a specialized Vaccines & Biologicals Supplier & Service for Ireland, Jiangxi Serum Pharma Industries Co., Ltd. understands the rigorous standards required by the Health Products Regulatory Authority (HPRA) and the EMA.
Ireland’s biopharma sector is not just about manufacturing; it’s about innovation. The country has seen a massive shift toward "Bioprocessing 4.0," integrating AI and digital twins into production. Our role as a supplier is to bridge the gap between high-capacity manufacturing in China and the specific clinical needs of the Irish healthcare system (HSE) and private research institutions in Dublin, Cork, and Galway.
Established Year
Global Clients
Verified Suppliers
Annual Turnover
The global vaccines market is projected to reach USD 125 billion by 2028, driven by mRNA advancements and personalized immunotherapy. For Ireland, the focus is on advanced therapy medicinal products (ATMPs). As a key supplier, we are evolving our portfolio to include intermediates and raw materials that support these next-generation treatments.
Integration of single-use technologies (SUT) to increase manufacturing flexibility. We are moving toward modular supply chain solutions that allow Irish labs to scale from pilot to commercial production rapidly.
Diversification of API sourcing to mitigate geopolitical risks. Our multi-site manufacturing partners ensure that a supply chain disruption in one region won't halt the flow of critical vaccines to Ireland.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts. Our Ireland-facing services focus on high-potency APIs and GMP-certified finished dosages.
Send Inquiry NowCustomized pre-mix solutions for vaccine stabilization and efficient formulation in Irish manufacturing suites.
Read MoreEnhancing API solubility and stability through advanced co-crystallization technologies for better bioavailability.
Read MoreState-of-the-art microbial and cell-culture fermentation processes for high-yield biological production.
Read MoreExploring the shift toward sustainable vaccine adjuvants in the European Union market...
Learn MoreWhy this critical molecule remains a cornerstone for respiratory therapy in modern medicine...
Learn MoreFDA approval of Eli Lilly's orforglipron marks a historic shift in metabolic disease treatment...
Learn MoreA: Yes, all our vaccines and biological products are manufactured in GMP-certified facilities that meet or exceed European Medicines Agency (EMA) standards, ensuring compliance for the Irish market.
A: We utilize validated thermal packaging and real-time IoT monitoring to ensure that vaccines and biologicals remain within the required temperature range throughout the entire transit to Ireland.
A: Absolutely. We provide comprehensive CMC (Chemistry, Manufacturing, and Controls) documentation, stability data, and Certificates of Analysis (CoA) to support clinical trial applications in Ireland.
A: Depending on the product type (API vs. finished dosage), lead times typically range from 4 to 8 weeks, including rigorous quality testing before dispatch.
